Earnings Call Summary | Evogene(EVGN.US) Q1 2024 Earnings Conference
Earnings Call Summary | Evogene(EVGN.US) Q1 2024 Earnings Conference
The following is a summary of the Evogene Ltd. (EVGN) Q1 2024 Earnings Call Transcript:
以下是Evogene Ltd.(EVGN)2024年第一季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
Evogene reported total revenue of approximately $4.2 million in Q1 2024, a significant increase from $0.6 million in Q1 2023.
Loss reduced to $3.8 million in Q1 2024, showing a decrease of 46% from the $7 million in Q1 2023.
Estimated cash use for 2024 excluding Biomica and Lavie Bio is predicted to be around $8 million, a 36% decrease year-over-year.
The closure of Canonic's operation was finalized, resulting in an annualized saving of $1.5 million.
Evogene報告稱,2024年第一季度的總收入約爲420萬美元,較2023年第一季度的60萬美元大幅增加。
2024年第一季度的虧損減少至380萬美元,較2023年第一季度的700萬美元下降了46%。
預計2024年的現金使用量約爲800萬美元,不包括Biomica和Lavie Bio,同比下降36%。
Canonic業務的關閉已經完成,每年節省了150萬美元。
Business Progress:
業務進展:
Partnerships with Verb Biotics and The Kitchen FoodTech Hub have been established and Finally Foods has been set up.
Casterra secured agreements with African and Brazilian seed growers to fulfill standing orders by the end of 2024.
Launch of Phase I clinical trial results for Biomica's BMC128 microbiome therapeutics at the 2024 ASCO Conference is in pipeline.
Lavie Bio initiated a new collaboration with Syngenta and received $2.5 million from Corteva.
AgPlenus announced a new collaboration with Bayer as operations of Canonic ceased due to challenging market conditions in the medical cannabis sector.
Evogene is planning to build an inventory for 2025, resourced initially by Evogene and later by partners' revenues.
The company conveys confidence in the uniqueness and versatility of their Computational Biology Platform (CBP) technology, aiming to enhance it through increasing number of partnerships.
已經與Verb Biotics和The Kitchen FoodTech中心建立了合作伙伴關係,Finally Foods也成立了。
Casterra與非洲和巴西的種子種植者達成協議,以在2024年底之前履行常規訂單。
Biomica 的 BMC128 微生物組療法在 2024 年 ASCO 會議上發佈的 I 期臨床試驗結果正在進行中。
Lavie Bio啓動了與先正達的新合作,並從Corteva獲得了250萬美元。
AgPlenus宣佈與拜耳進行新的合作,因爲由於醫用大麻領域的市場條件艱難,Canonic的業務停止了。
Evogene計劃建立2025年的庫存,最初由Evogene提供資源,後來由合作伙伴的收入提供資源。
該公司對其計算生物學平台(CBP)技術的獨特性和多功能性充滿信心,旨在通過增加合作伙伴關係來增強該技術。
More details: Evogene IR
更多詳情: Evogene IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。